Unfortunately, the promiscuous engagement of the canonical substrate-binding site with a broad array of Hsp70 substrates, in either ATP-dependent or holdase modes, has precluded targeting Hsp70’s canonical actions as an effective therapeutic approach for neurodegenerative diseases. This evidence concerns the gene HSPA1A and neurodegenerative disease.